Effect of diease-modifying and biological drugs on intestinal immunity in patients with rheumatoid arthritis.
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000012200
- Lead Sponsor
- Katayama Orthopadic Rheumatology Clinic
- Brief Summary
Patients of Rheumatoid arthritis(RA), dividing into two pathogenisis of rapid rediographic progression(RRP) and non-RRP, were assyed for their IgA and IgG antibody activity to E coli-LPS, Gingivalis LPS and St. pyogenes PG-PS and compared with those of normal person. No significant differenses was obserbed between RA and normal. Correlation between RA disease markers,RF, ESR, CRP and also DAS28-ESR to an anti IgA/IgG ratio of Pg-LPS correlated in RRP. In contrast,the ratio to E. coli-LPS and also PG-PS correlated with the disease markers in non-RRP. Results shwed that multiple embironmental pathogen, which overwhelm the host antibody defense function, cotribute independently or concomitantly to evoking disease markers and aggravationg disease activity, and affect disease outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Not provided
RA patients having complication other than rheumatoid arthritis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a) Therapeutic effects of DMARDs and biologicals will be evaluated by EULAR and ACR criteria. b) Antibody response to E. coli and LPS will be assayed to determine intestinal immune function of individual pateints, whereas serum LPS levels will be determined to measure intestinal barrier function. In addition, serum TNF, IL-6 and anti-CCP antibody levels will be assayed to study the potential linkage between intestinal immune function and inflamation. c) Effect of RMARDs and biologicals on intestinal immune function will be evaluated in individual patients for a 6-month period as well as for their their therapeutic effect.
- Secondary Outcome Measures
Name Time Method This study will provide basic data to study a new concept that lowered immune function may be the fundamental common disorder in autoimmune diseases.